Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORMA
2024-517880-22-00Phase 3Authorised
- Sponsor
- Military Institute of Medicine – National Research Institute
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Ketosteril in nephrosis and protein-energy wasting (PEW) (2 arms), sponsored by Military Institute of Medicine – National Research Institute. Primary endpoint: Change in lean body mass from baseline within 6 weeks after enrollment in the study (non-inferiority). Planned start Dec 2024; status: authorised.
02
Drugs
Ketosteril
03
Conditions
nephrosisprotein-energy wasting (PEW)
Beyond the preview
Go deeper on 2024-517880-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517880-22-00.